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Abstract: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a predominantly type 2 
inflammation-mediated disease of the nasal mucosa and paranasal sinuses with an under- 
recognized clinical, humanistic, and economic burden. Patients with CRSwNP experience 
a high symptom burden, including nasal congestion, loss of smell, and rhinorrhea, which has 
a negative impact on physical and mental health-related quality of life, including sleep 
quality. Existing medical and surgical interventions, including local and systemic corticos-
teroids and endoscopic sinus surgery, may be associated with recurrence of nasal polyps and 
associated symptoms and with an increased risk of short- and long-term adverse effects, 
especially with repeated or long-term use. Because type 2 inflammation is implicated in the 
pathogenesis of several coexisting diseases, patients with CRSwNP often have comorbid 
asthma and/or nonsteroidal anti-inflammatory drug-exacerbated respiratory disease. These 
patients, as well as those with high corticosteroid use and/or sinonasal surgical history, have 
more severe disease and associated symptom burden and represent a difficult-to-treat popu-
lation under the existing management paradigm. This article reviews the clinical, humanistic, 
and economic burden of CRSwNP; it highlights the unmet need for effective and safe 
CRSwNP therapies that effectively control symptoms and minimize recurrence by targeting 
the underlying type 2 inflammatory disease pathophysiology. 
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Introduction
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic inflammatory disease 
of the nasal mucosa and paranasal sinuses that is associated with significant morbidity 
and reduced health-related quality of life (HRQoL).1–3 The pathophysiology of 
CRSwNP is associated with local (sinonasal) and systemic (lower airway) inflamma-
tion, with persistent symptoms of nasal congestion, rhinorrhea, and loss of smell that 
have a significant impact on HRQoL.4 Most patients with CRSwNP show evidence of 
type 2 airway inflammation, and these patients have the highest disease burden.5–8 As 
a result of the shared type 2 inflammatory pathway implicated in several coexisting 
diseases, patients with CRSwNP often have comorbid asthma and/or nonsteroidal anti- 
inflammatory drug-exacerbated respiratory disease (NSAID-ERD).
The disease burden with significantly lower physical and mental HRQoL than 
population norms is particularly high in CRSwNP. This is particularly in patients 
with comorbid asthma and/or NSAID-ERD9 and in patients who need repeated 
treatment with corticosteroids and/or sinonasal surgeries to alleviate its uncon-
trolled symptoms. The impact on HRQoL is comparable with other chronic diseases 
such as chronic obstructive pulmonary disease (COPD), asthma, and diabetes.10,11
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CRSwNP can be difficult to treat in patients with the 
highest burden. The current treatment paradigm involves 
corticosteroids and/or sinonasal surgery, but these options 
may be associated with recurrence of nasal polyps, and 
patients may require revision surgery. Additionally, there 
exist non-negligible risks associated with both repeated 
steroid use and surgery.12,13 A qualitative study reported 
that patients can become frustrated with the management 
of their disease and often feel that the impact on their 
quality of life is not fully recognized.14
For this review, a targeted search of the literature was 
performed to examine the burden of disease for CRSwNP. 
Although previous literature reviews have focused on spe-
cific aspects of unmet need, this review evaluates 
a broader set of outcomes, with a focus on burden: the 
clinical, humanistic, and economic aspects of the disease, 
and the impact on HRQoL of the patients. We searched 
MEDLINE (via PubMed) and Embase for articles using 
search terms including “nasal polyposis,” “rhinosinusitis,” 
“chronic rhinosinusitis,” and “chronic rhinosinusitis with 
nasal polyps,” and articles were chosen for inclusion based 
on their relevance to the topic. We also referenced expert 
position papers. In this targeted literature review, we high-
light the epidemiology and pathology of CRSwNP, exam-
ine the clinical, humanistic, and economic burden of the 
disease, and close with a review of the current treatment 
paradigm and its limitations.
Epidemiology and Pathology
The proportion of adults in the USA15 who would meet the 
symptom criteria of chronic rhinosinusitis (CRS) is esti-
mated to be 2.1% and, based on population studies, it is 
estimated to be between 2.1% and 4.3% in Europe.16,17 
Among all patients with CRS, approximately 20–30% 
have CRSwNP.3,18 Overall, given the requirement for 
nasal endoscopy to make a reliable diagnosis, prevalence 
estimates for nasal polyps based on questionnaire data may 
not represent an accurate estimate.19
CRSwNP is typically a disease of middle age, with 
a peak incidence between the fourth and fifth decades of 
life.1 Despite the presence of nasal symptoms, which 
develop slowly, many patients with CRSwNP do not 
seek medical attention for their sinonasal symptoms.17 
Thus, many patients diagnosed in middle age may have 
severe disease in spite of experiencing symptoms for dec-
ades; among those who are diagnosed at a younger age, 
there is the expectation of a long-term burden of illness on 
the patient. Although females are less likely to be affected 
than males, females are more likely than males to experi-
ence greater severity of symptoms.3
The etiology of CRSwNP is yet to be fully elucidated. 
The presence of persistent symptoms such as nasal con-
gestion, loss of smell, and rhinorrhea for >3 months is the 
basis for diagnosing CRSwNP.20 Postnasal drip is also 
common, whereas facial congestion and pain are 
variable.20,21 It should be noted that severe symptoms do 
not occur at the same intensity throughout the disease 
severity spectrum.
CRS is not a homogeneous disease but rather 
a heterogeneous disorder with multiple inflammatory 
endotypes.22 Affected patients have bilateral benign ede-
matous polyps extending from the paranasal sinuses to the 
nasal cavity, with increased levels of cytokines and 
mediators23 and an intense inflammatory infiltrate as 
a typical finding.1 In Western countries, CRSwNP is 
most often associated with eosinophilic inflammation 
whose characteristics include elevated levels of immuno-
globulin E (IgE), interleukin (IL)-4, and IL-5 compared 
with patients without nasal polyps.22,24,25 The polyclonal 
and preferential activation of T helper type 2 cells, 
a feature of this inflammatory pattern, is implicated in 
the amplification of mucosal inflammation26 and is typical 
of patients with more severe CRSwNP. Although of 
a predominantly eosinophilic phenotype, with a less com-
mon neutrophilic inflammatory subtype observed, no spe-
cific genetic or environmental factors are strongly 
associated with the disorder and defects in the sinonasal 
epithelial barrier; bacterial exposure and dysregulation of 
the immune system may all play a role.1,3,24 Patients with 
allergic fungal rhinosinusitis, characterized by elevated 
antifungal IgE and eosinophilic mucus, represent 
a unique subgroup presenting with unilateral CRSwNP.27
CRSwNP symptoms are associated with local and sys-
temic inflammation.4 Localized inflammation is character-
ized by a dysfunctional interaction between the sinonasal 
mucosa and the environment. CRSwNP is associated with 
higher rates of colonization with Staphylococcus aureus in 
the upper airway leading to biofilm formation, immune 
dysregulation, inflammation, and barrier dysfunction, con-
tributing to recalcitrant disease.23,28,29 Systemic immuno-
logic cross-talk may play a role, with symptoms of CRS 
resulting from simultaneous irritation of the upper and 
lower airways.4 There is also a suggestion that reflexes 
mediated via the nervous system, possibly via the nodose 
ganglion/vagus nerve, may play a role as occurs in 
asthma.30
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Clinical Burden
The clinical presentation of CRSwNP may include nasal 
congestion, rhinorrhea/postnasal drip, facial pain or head-
ache, impaired sense of smell, and sleep disturbance or 
fatigue; uncontrolled disease is defined as the persistence 
of these symptoms on most days of the week and the need 
for rescue treatment.20 The clinical burden of CRSwNP can 
be greatly impacted by the presence of comorbid disease.
Bilateral eosinophilic CRSwNP is often associated 
with non-allergic asthma and intolerance to NSAIDs; 
NSAID-ERD represents a serious and recurrent clinical 
form of the disease with pronounced disease burden 
based on objective measures.1,31 In patients with 
CRSwNP, up to 65% and 26% have comorbid asthma 
and NSAID-ERD, respectively.1,26,32–34 Among patients 
with CRSwNP and comorbid asthma or NSAID-ERD, 
increased disease severity associated with type 2 inflam-
mation is additionally characterized by recurrence of nasal 
polyps, higher rates of revision surgery, systemic corticos-
teroid (SCS) dependence, and poor asthma control.35,36
In patients with CRSwNP, the prevalence of comorbid 
asthma is reported to be up to 65%,22,32,37 much higher 
than the prevalence of asthma in the general US popula-
tion, which is 8.5%.38 In a recent study involving patients 
with severe asthma, 43% also suffered from CRSwNP.39 
CRSwNP has been associated with adult-onset asthma 
(onset after 12 years of age) or late-onset asthma (onset 
after 40 years of age).40 The prevalence of CRSwNP and 
that of comorbid asthma increased with age and was 
particularly evident in those aged ≥40 years.41 Patients 
with late-onset asthma were less frequently atopic and 
more likely to have CRSwNP.39
NSAID-ERD is one of the most serious, recurrent, and 
treatment-resistant comorbidities associated with 
CRSwNP, and it is often found in association with other 
type 2 inflammatory diseases such as asthma.1,26,31 
NSAID-ERD in particular is thought to place an especially 
high clinical burden on affected patients.9,34 The frequent 
recurrence of nasal polyps after surgery and a requirement 
for high-dose SCS to manage asthma, if present, reflect the 
persistent and aggressive nature of the disease.42
In the USA, it is estimated that patients with CRSwNP 
with NSAID-ERD undergo an average of three sinus opera-
tions during their lifetime.33 In addition to undergoing more 
operations, those with NSAID-ERD were also younger at 
the time of their first surgery compared with patients with 
CRSwNP without NSAID-ERD. One study of patients with 
CRS undergoing revision sinus surgery found that the pre-
sence of nasal polyps was associated with the presence of 
comorbid aspirin sensitivity, with additional evidence of 
disease burden in terms of higher endoscopy scores, com-
puted tomography (CT) scores, and absolute eosinophil 
counts.31 Thus, NSAID-ERD is a difficult-to-treat disease 
both from a pharmacologic and a surgical perspective.43
Humanistic Burden
From a patient perspective, CRSwNP carries a substantial 
burden that has a significant impact on HRQoL. Compared 
with those without CRSwNP, patients with CRSwNP 
experience higher symptom scores and greater severity of 
clinical disease.22,25,34 The presence of CRSwNP is not 
only associated with greater burden of disease at presenta-
tion but also with worse disease severity despite sinonasal 
surgery.31
Patients with CRSwNP suffer in their overall health in 
a way that cannot be described by disease-specific mea-
sures alone. The impact of CRSwNP on overall HRQoL 
has been reported to be comparable with other chronic 
diseases such as COPD, asthma, and diabetes.10,11 In 
a study comparing health state utility values, CRS demon-
strated impairment on a par with end-stage renal disease, 
moderate asthma, Parkinson’s disease, and coronary artery 
disease.44 A study using the 36-Item Short-Form Health 
Survey (SF-36) questionnaire reported that patients with 
CRS had lower overall scores compared with population 
norms, and they had significantly worse bodily pain and 
social functioning scores than those with congestive heart 
failure, COPD, angina, or sciatica.45 Another study, also 
utilizing SF-36, reported that patients with CRSwNP had 
worse physical and mental health compared with popula-
tion norms.9
CRSwNP and asthma are individually associated with 
substantial disease burden, and patients with CRSwNP and 
comorbid asthma have an even greater combined burden 
that has a serious impact on HRQoL.9,46 The presence of 
asthma resulted in significantly higher symptom scores 
compared with patients without asthma.25 Compared with 
non-asthmatic controls, patients with CRSwNP scored sig-
nificantly lower in the Mini Asthma Quality of Life 
Questionnaire, irrespective of asthma.32 In one study, 
poor asthma control correlated with high sinus CT scores 
in CRSwNP.47
CRSwNP is frequently associated with severe olfactory 
loss. One of the most troublesome and recalcitrant symp-
toms in patients with CRSwNP, loss of smell, correlates 
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with disease severity and has a substantial impact on 
HRQoL.48 A Korean study that assessed HRQoL and 
psychological symptoms in patients with CRSwNP found 
that olfactory dysfunction may also have significant effects 
on psychological health, including higher levels of depres-
sion, anxiety, and phobia.48 A qualitative study on olfac-
tory loss found that olfactory impairment exposes 
individuals to potential environmental dangers such as 
the inability to identify expired foods or to detect smoke 
or gas, reduces enjoyment of food, and can interfere with 
the evocation of memories.49 CRSwNP not only has 
a major impact on general and disease-specific HRQoL 
but also impairs sleep quality and nasal patency, and 
increases daytime sleepiness and the risk of sleep 
apnea,50 all of which may negatively affect patient mental 
health.
A qualitative study that evaluated patient experiences 
of CRS found that many patients are self-conscious about 
their condition due to the impacts of constant nasal con-
gestion and/or discharge; other patients experienced 
depression. Loss of confidence was common due to the 
inability to speak clearly in social and work situations; 
poor or disrupted sleep occurred frequently resulting in 
problems with fatigue and ability to concentrate; loss of 
smell and taste reduced enjoyment in socializing and eat-
ing out; participants described forgetting what it was like 
to be normal; many participants reported experiencing 
frustrations with the primary care management of their 
symptoms; and many participants reported that health 
care professionals failed to recognize the impact on 
HRQoL.14
Economic Burden
CRSwNP has significant direct and indirect costs to 
patients and society. Among patients with CRSwNP and 
comorbid asthma or NSAID-ERD, increased disease 
severity associated with type 2 inflammation is addition-
ally characterized by higher costs and health care 
utilization.35 NSAID-ERD, in particular, is thought to 
place an especially high financial burden on affected 
patients.34 In the USA, total annual health care costs 
among patients with CRSwNP were $11,507, significantly 
higher than the reference population, leading to a total cost 
of $5.7 billion.35 CRSwNP also has indirect and produc-
tivity-related costs. Costs to the patient relating to absen-
teeism, presenteeism, and lost work productivity are likely 
to be substantial, with CRS associated with an average of 
4.8 days of missed work per year.4 Indeed, the mean 
annual indirect costs for patients with inadequately con-
trolled CRSwNP have been estimated at $7182 per 
patient,51 indicating that the total cost of CRSwNP 
per year exceeds $15,000. In a recent study in Europe, 
direct costs for patients with CRSwNP were €1501 per 
patient/year, with indirect costs of €5659 per patient/year, 
largely due to outpatient/hospital visits and productivity 
loss, respectively.52
A health economic analysis of SCS use in patients with 
CRSwNP that considered the impact of adverse events 
found that the breakeven threshold for which surgery 
was favored over medical therapy occurred when >1 
SCS course was given every 2 years.53 The threshold 
number of SCS courses per year at which risks of medical 
therapy exceed risks of surgery were 0.21 for CRSwNP 
alone, 0.55 for CRSwNP with asthma, and 1.82 for 
CRSwNP with asthma and NSAID-ERD.13 Analyses of 
this nature provide evidence-based thresholds for clini-
cians to utilize when making clinical decisions with 
patients on the relative utility of surgery versus repeated 
corticosteroid use.
Current Treatment Paradigm and 
Its Limitations
Evidence-based recommendations for the management of 
CRSwNP call for the use of intranasal and oral corticos-
teroids/SCS where the goal of treatment is to achieve and 
maintain clinical disease control and avoid 
complications.4,20 Disease control is defined as the 
absence of symptoms or symptoms no longer being both-
ersome, together with a healthy mucosa and need for 
topical medication alone.4 When suboptimally controlled, 
CRSwNP worsens the course of lower airway disease.53
There is good evidence that both intranasal corticoster-
oids and SCS are effective to some extent in the manage-
ment of CRSwNP. However, there are also limitations with 
these treatments, and their short-lived benefits need to be 
balanced with the need for long-term control and 
safety.13,53 Existing data support the infrequent use of 
SCS in the immediate- and short-term periods for patients 
with CRSwNP; however, their long-term benefits are 
limited.53 SCS treatment can lead to serious treatment- 
related adverse effects, and even short-term corticosteroid 
use is associated with an increased risk of acute complica-
tions such as sepsis, venous thromboembolism, and 
fracture.54,55
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If CRSwNP is not controlled in a patient after a period 
of time, a CT scan and surgery may be considered.4 While 
endoscopic surgery has greatly improved the safety of 
sinonasal surgery, significant risks remain, with minor 
complications reported in 5% of routine endoscopic inter-
ventions and major complications reported in 0.5–1% of 
them.12 The long-term revision rates for endoscopic sinus 
surgery for CRS exceed 15%, with the presence of nasal 
polyps having the largest impact on the risk of revision 
surgery with success rates reported of around 50–70%.20,56
The current treatment paradigm for the management of 
CRSwNP has significant limitations. The recurrence rate 
of CRSwNP after surgery ranges from 20% to 60% within 
18 months to 4 years follow-up35 to 79% over a 12-year 
period.57 Recurrences are particularly common in patients 
with more severe disease such as that associated with 
comorbid asthma or who have undergone prior 
surgeries.20,53 Among patients with CRSwNP alone, 
CRSwNP with asthma, and CRSwNP with asthma and 
NSAID-ERD, median times to revision surgery were 20, 
11, and 7 years, respectively.13 Median times to polyp 
recurrence were 20, 4, and 0.66 years, respectively. 
Intense eosinophilia together with asthma and NSAID- 
ERD are associated with a 4.5-fold increased risk of recur-
rence following initial surgery.1
Many patients with prior SCS use or surgery remain 
symptomatic. Among patients who undergo endoscopic 
sinus surgery for CRSwNP, failure rates, defined as persis-
tent symptoms for >6 months after surgery, are high, with 
one study reporting 23% of patients with persistent symp-
toms after surgery.53 In a qualitative study of patient 
perspective on revision surgery, patients who had under-
gone more surgeries were more pessimistic in their expec-
tations and objectives for surgical treatment (Saydy, 
unpublished). In a qualitative study evaluating patient 
experiences of CRS, patients often described sinus surgery 
as a temporary solution, with the expectation that surgery 
may not fully resolve symptoms or that symptoms would 
return and further surgery may be required.14 Indeed, the 
data support this, as 59% of the European GALEN cohort 
of patients with CRSwNP required revision surgery and 
7% of patients had undergone ≥4 surgical procedures.40
Patients with persistent CRSwNP symptoms despite 
appropriate medical and/or surgical management are 
defined as difficult to treat.4 Due to the chronic and recur-
ring nature of CRSwNP, even after surgery and existing 
medical approaches that focus on non-specific reduction of 
local inflammation (and lower airway inflammation in the 
case of SCS), there is a medical need for targeted treat-
ment of nasal polyps and the underlying mechanisms of 
chronic sinus inflammation. Despite available therapies, 
the burden of CRSwNP in adults is substantial and demon-
strates an unmet need for effective management strategies. 
Novel, well-tolerated therapies that provide effective 
symptom control and minimize recurrence rates of nasal 
polyps are needed. A number of biologic therapies target-
ing type 2 inflammation have been investigated in 
CRSwNP.5,58–62 Among these, phase 3 trials conducted 
in patients with CRSwNP uncontrolled with intranasal 
corticosteroids have demonstrated the efficacy of mono-
clonal antibody therapies targeting IL-4/IL-13 (dupilu-
mab), IgE (omalizumab), and IL-5 (mepolizumab).58,63,64 
The primary endpoints of these trials (reduction in nasal 
polyp score [NPS] and nasal congestion/obstruction score) 
were met with significant improvements in the treated 
patients versus placebo. Significant improvements in 
other measures including smell and disease-specific qual-
ity of life (SNOT-22) were also seen with all three drugs. 
Importantly, these phase 3 trials recruited a significant 
proportion of patients with comorbid asthma (48–71%) 
and with prior surgery (58–100%).
Dupilumab and omalizumab have received regulatory 
approval in the EU and US as add-on therapy for adult 
patients with severe CRSwNP inadequately controlled by 
intranasal corticosteroids, while mepolizumab is currently 
under regulatory review. The role of biologic therapy in 
the management of CRSwNP is currently evolving. 
Questions over the timing of biologic therapy versus sur-
gery, the presence of comorbidities, and precise choice of 
biologic in individual patients remain to be determined, as 
highlighted in a recent publication by the European Forum 
for Research and Education in Allergy and Airway 
Diseases.65 Nevertheless, the availability of these targeted 
therapies is likely to lead to improvements in the manage-
ment of patients with CRSwNP with unmet needs despite 
existing standard of care.
Conclusion
CRSwNP is a chronic predominantly type 2 inflammation- 
mediated disease with an under-recognized clinical, 
humanistic, and economic burden despite the recalcitrant 
nature of the disease and the associated high symptom 
burden. Existing medical and surgical interventions, 
including intranasal corticosteroids and SCS and endo-
scopic sinus surgery, may be associated with recurrence 
and potential side effects and risks. As a result of the 
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shared underlying type 2 inflammation implicated in the 
pathogenesis of several coexisting diseases, patients with 
CRSwNP often have comorbid asthma and/or NSAID- 
ERD. These patients, as well as those with high corticos-
teroid use and/or sinonasal surgical history, have more 
severe disease and associated symptom burden and repre-
sent a difficult-to-treat population under the existing man-
agement paradigm. There exists an unmet need for 
effective and well-tolerated therapies for CRSwNP that 
effectively control symptoms, reduce NPS, improve 
HRQoL, and minimize relapse by targeting the underlying 
type 2 disease pathophysiology, thereby providing 
a holistic disease control. The judicious introduction of 
targeted biologic therapies into the treatment paradigm 
should lead to improvements in the lives of patients with 
this burdensome condition.
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